body mass index

Overview

Body mass index (BMI) is a clinical metric used to estimate relative adiposity from an individual’s weight and height. It is calculated as weight in kilograms divided by height in meters squared (kg/m²). In clinical and epidemiologic practice, BMI is widely used to classify underweight, normal weight, overweight, and obesity, and it serves as a practical surrogate marker for excess body mass in large populations and routine care.

Although BMI does not directly measure body composition, fat distribution, or metabolic health, it is strongly associated with a range of medical outcomes, including type 2 diabetes, hypertension, cardiovascular disease, inflammation, and chronic kidney disease. Because of its simplicity and standardization, BMI is often used alongside other measures such as waist circumference, body composition, and waist-to-height ratio to refine risk assessment, especially in settings where obesity-related risk may vary across sex, age, and disease context.

Recent Publications Summary

Recent studies evaluated body mass index (BMI) as a clinical correlate, covariate, or predictor across dermatology, reproductive health, renal disease, imaging, radiotherapy, and metabolic trials. In psoriasis, BMI was examined with restricted cubic spline models in a prospective registry cohort of patients starting biologics, methotrexate, or phototherapy; obesity was associated with lower early response odds for biologics and methotrexate, while the BMI-response association appeared most evident in biologics 42592795Aug. In women from NHANES, higher BMI was associated with greater prevalence of infertility, alongside a novel weight-adjusted waist index analysis 42566560Aug. In a combined Mendelian randomization and clinical cohort study of progression from type 2 diabetes mellitus to end-stage renal disease, elevated BMI was identified as a causal risk factor in genetic analyses and as an independent risk factor in the retrospective cohort 42556871Aug.

BMI was also assessed as a marker of adiposity and body composition. In healthy aging Caucasian women, DXA-based fat mass measurements were used to test how well BMI classifies obesity; BMI-defined obesity was substantially less frequent than DXA-defined obesity, indicating notable discordance between BMI and direct body fat assessment 42484670Jul. In older adults from a multi-cohort diffusion MRI study, BMI was linked to white matter microstructure, but the associations were inconsistent across diffusion metrics compared with stronger, more widespread effects for hypertension and heart disease 42535262Jul. In vulvar cancer patients treated in the frog-leg position, BMI was analyzed for correlation with setup errors during surface-guided radiotherapy, alongside improved setup accuracy with SGRT 42503572Jul.

Other publications used BMI to define eligibility or to contextualize treatment effects. A randomized controlled trial of catechin plus inulin enrolled adults with visceral obesity defined by visceral fat area and BMI ≥23 kg/m2, though the primary outcome focused on visceral fat area rather than BMI change 41830022Mar. In a phase 3 trial of mazdutide in Chinese adults with type 2 diabetes, the enrolled population had a mean BMI of 28.2 kg/m2, and treatment produced significant reductions in hemoglobin A1c and weight loss versus placebo 41407859Dec. BMI was also incorporated into a multimorbidity prediction framework in UK Biobank, where combined general and central obesity conferred the highest risk, and central obesity added risk discrimination mainly within the overweight BMI category 42457618Jul. In children and adolescents, BMI was investigated as a mediator in the relationship between vitamin D levels and headache risk, reflecting its proposed role in metabolic and inflammatory pathways 42065159May.

What Changes, What Holds

1. BMI now appears to matter mainly as a response modifier rather than a general predictor
NEW DIRECTION Psoriasis treatment response adds a use of BMI that goes beyond its established role as a broad risk surrogate: higher BMI, especially obesity, was linked to poorer early response to some therapies, with the clearest signal in biologics and a similar but less consistent pattern for methotrexate 42592795Aug. The infertility and kidney-disease findings extend BMI’s prognostic reach into new clinical settings, but they do not overturn the baseline account of BMI as a practical correlate of adiposity and adverse metabolic risk 42566560Aug42556871Aug.

2. Direct body-fat measurement shows BMI can miss obesity in older women
METHOD DXA-based fat mass assessment does not change what BMI is used for, but it sharpens the known limitation that BMI is only a surrogate for adiposity, not a direct measure of body composition 42484670Jul. The discordance between BMI-defined and DXA-defined obesity shows that BMI can underclassify excess fat in some populations, reinforcing the need to pair it with direct or central adiposity measures rather than treating it as interchangeable with body-fat measurement. The MRI and radiotherapy analyses are additional applications of BMI as a covariate, not new biological roles 42535262Jul42503572Jul.

3. BMI is being used to define trial populations and refine combined obesity risk models
REINFORCES Enrollment thresholds using BMI and analyses that place BMI alongside visceral or central obesity confirm BMI’s continuing role as a practical clinical classifier and trial eligibility metric 41830022Mar41407859Dec42457618Jul. The multimorbidity and headache work does add context: BMI can help stratify risk when combined with central adiposity or metabolic mediators, but that fits the baseline view that BMI is useful yet incomplete. None of these findings displace its established use; they mainly extend where it is being applied and how it is adjusted for in models 42065159May.

Overview update candidates: BMI can be used as a predictor of treatment response in psoriasis; and BMI-defined obesity may substantially undercount adiposity compared with DXA in some older women.